Anti-TNF-α treatment using a monoclonal antibody (infliximab) against a TNF receptor appears to repress tumor growth, induce tumor degeneration, and inhibit bone metastases in breast cancer-induced mice [77]. Here, TNF is linked to breast carcinoma.